Search Results - "Conteduca V"

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.

Authors: Cursano, M. C. Conteduca, V. Scarpi, E. et al.

Source: Scientific Reports. 5/5/2022, Vol. 12 Issue 1, p1-8. 8p.

Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy.

Authors: Conteduca, V. Medri, M. Mazzoni, L. et al.

Source: Cancer Immunology, Immunotherapy. Jun2022, Vol. 71 Issue 6, p1545-1548. 4p.

2488P Genomic landscape in locally advanced prostate cancer (LAPC) and clinical implications.

Authors: Conteduca, V. Orlando, F. Garofoli, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1349-S1349. 1p.

2430P Prognostic impact of variants of uncertain significance (VUS) in homologous recombination repair (HRR) genes in prostate cancer (PC) outcome: A real-word Multicenter Study.

Authors: Conteduca, V. Garofoli, M. Natalicchio, M.I. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1320-S1320. 1p.

LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study).

Authors: Conteduca, V. Brighi, N. Gurioli, G. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1259-S1259. 1p.

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Authors: Conteduca, V. Wetterskog, D. Sharabiani, M. T. A. et al.

Source: Annals of Oncology. Jul2017, Vol. 28 Issue 7, p1508-1516. 9p. 3 Charts, 2 Graphs.

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors: Salvi, S. Conteduca, V. Gurioli, G. et al.

Source: Molecular Diagnosis & Therapy. Feb2016, Vol. 20 Issue 1, p1-12. 12p.

615P Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC).

Authors: Gurioli, G. Conteduca, V. Brighi, N. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS654-S655. 2p.

589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC).

Authors: Perez Navarro, E. Conteduca, V. Gonzalez del Alba, A. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS637-S638. 2p.

This result is not displayed to guests.
Login for full access.

Corrigendum to "589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)": [Annals of Oncology 32 suppl. 5 (2021) S637-S638].

Authors: Perez-Navarro, E. Conteduca, V. González-del-Alba, A. et al.

Source: Annals of Oncology. Apr2022, Vol. 33 Issue 4, p455-455. 1p.

601P The prognostic role of longitudinal assessment of plasma androgen receptor (AR) copy number (CN) in metastatic castration-resistant prostate cancer (mCRPC): Analysis from a prospective biomarkers trial.

Authors: Brighi, N. Conteduca, V. Gurioli, G. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS645-S645. 1p.

583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.

Authors: Conteduca, V. Scarpi, E. Wetterskog, D. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS633-S633. 1p.

93PD - Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients.

Authors: Del Re, M. Conteduca, V. Crucitta, S. et al.

Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv26-v26. 1p.

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Authors: Salvi, S Casadio, V Conteduca, V et al.

Source: British Journal of Cancer. 5/12/2015, Vol. 112 Issue 10, p1717-1724. 8p. 2 Charts, 3 Graphs.

2496P Evaluating treatment efficacy in metastatic hormone-sensitive prostate cancer with visceral disease: A systematic review and network meta-analysis.

Authors: Neola, G. Flauto, F. Caso, C. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1352-S1353. 2p.

692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC).

Authors: Cattrini, C. Lozano Mejorada, R. Conteduca, V. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS547-S548. 2p.

T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia.

Authors: Russi, S. Lauletta, G. Serviddio, G. et al.

Source: Clinical & Experimental Immunology. May2013, Vol. 172 Issue 2, p254-262. 9p.

2680eP Metastatic fumarate hydratase-deficient renal cell carcinoma (FHRCC): outcome on first-line immune checkpoint inhibitor (ICI) combination: a multicenter retrospective study (FUMAHRE study).

Authors: Guida, A. Bimbatti, D. Di Marco, A. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1430-S1430. 1p.

2650P Metastasis-directed therapies (MDT) for oligometastatic (OM) and oligoprogressive (OP) Renal Cell Cancer (RCC) patients with extra-lung metastases: The KAIROS study.

Authors: Dimino, A. Rizzo, M. Fazio, I. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1420-S1420. 1p.